The company highlighted pipeline developments.
Moderna Therapeutics has announced advances in its mRNA development pipeline. The mRNA program has pushed forward into phase 2, with infectious disease vaccine and oncology programs in phase I. The company’s pipeline consists of 19 mRNA drug candidates for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases.
Moderna’s Chief Executive Officer Stéphane Bancel made the following announcement at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco: “2016 was the year of mRNA vaccines in the clinic. 2017 was the year of several mRNA therapeutics in the clinic. In 2018, we will continue to evolve our pipeline of mRNA therapeutics, specifically focusing on discovering new rare disease drug candidates, while remaining committed to advancing new vaccine development candidates to address serious unmet needs. We also will continue to work toward a summer 2018 opening and rolling scale-up of our GMP clinical mRNA manufacturing facility, which is a cornerstone of our long-term strategy to move multiple development programs simultaneously into and through phase 1, phase 2, and phase 3 clinical studies.”
Moderna has internally developed and partnered clinical programs with AstraZeneca and Merck with 700 subjects being treated by candidates in the company pipeline.
